Global Small Cell Lung Cancer Therapeutics Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Understanding the Disease
05.2 Classification
05.2.1 Small Cell Carcinoma
05.2.2 Combined Small Cell Carcinoma
05.3 Diagnosis
05.3.1 Physical Examination
05.3.2 Laboratory Tests
05.3.3 Chest X-ray
05.3.4 Sputum Cytology
05.3.5 CT Scan
05.3.6 Biopsy
05.3.7 Light and Electron Microscopy
05.3.8 Immunohistochemistry
05.4 Rate of Incidence and Prevalence
05.5 Staging
05.6 Management
05.7 Economic Burden
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Top Predictions
07.4 Five Forces Analysis
08 Pipeline Analysis
08.1 Key Information on the Pipeline Candidates
08.1.1 Palifosfamide (ZIO-201)
08.1.2 Ipilimumab+Etoposide+Cisplatin/Carboplatin
08.1.3 Ipilimumab
08.1.4 Enoxaparin Sodium
08.1.5 BAY1000394 (Roniciclib)
08.1.6 Nivolumab (ONO-4538/ BMS-936558)
08.1.7 BMS-986012
08.1.8 LY2940680
08.1.9 Sabarubicin (MEN 10755)
08.1.10 CAP7.1
08.1.11 SC16LD6.5
08.1.12 BIW-8962
08.1.13 AMG 479 (Ganitumab)
08.1.14 LY2510924
08.1.15 Trisenox
08.1.16 MGN1703
08.1.17 Tarextumab  (OMP-59R5)
08.1.18 BMN 673 (Talazoparib Tosylate)
08.1.19 NGR-hTNF
08.1.20 CPI-613
08.1.21 Alisertib (MLN8237)
08.1.22 Vismodegib (GDC-0449, Erivedge)
08.1.23 Cabozantinib (XL184 or Cometriq)
08.1.24 Selinexor  (KPT-330)
08.1.25 ADI-PEG 20 (Pegargiminase)
08.1.26 Etirinotecan Pegol (NKTR-102)
08.1.27 CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
08.1.28 NTX-010
08.1.29 Aldoxorubicin
08.1.30 HA-Irinotecan
08.1.31 Carfilzomib
08.1.32 Small Cell Lung Cancer Vaccine
08.1.33 GSK2879552
08.1.34 NV-344 (ME-344)
08.1.35 BMS-833923 (XL139)
08.1.36 PM01183 (Lurbinectedin)
08.1.37 LDE225 (Erismodegib or Sonidegib)
08.1.38 Belinostat
08.2 Timeline for Major Products under Development
08.2.1 Palifosfamide (ZIO-201)
08.2.2 Sabarubicin (MEN 10755)
09. Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others
10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11 Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
12 Geographical Segmentation
12.1 Small Cell Lung Cancer Market in Americas
12.1.1 Market Size and Forecast
12.2 Small Cell Lung Cancer Market in EMEA Region
12.2.1 Market Size and Forecast
12.3 Small Cell Lung Cancer Market in APAC Region
12.3.1 Market Size and Forecast
13 Buying Criteria
14 Market Growth Drivers
15 Drivers and their Impact
16 Market Challenges
17 Impact of Drivers and Challenges
18 Market Trends
19 Trends and their Impact
20 Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Bristol-Myers Squibb
20.2.2 GlaxoSmithKline
20.2.3 Menarini
20.2.4 Sanofi
20.2.5 ZIOPHARM Oncology
20.3 Other Prominent Vendors
21 Key Vendor Analysis
21.1 Bristol-Myers Squibb
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Key Product Offerings
21.1.4 Revenue by Geography
21.1.5 Business Strategy
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 GlaxoSmithKline
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Pipeline Products
21.2.7 Business Strategy
21.2.8 Key Information
21.2.9 SWOT Analysis
21.3 Menarini
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Pipeline Products
21.3.4 Recent Developments
21.3.5 SWOT Analysis
21.4 Sanofi
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 ZIOPHARM Oncology
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Recent Developments
21.5.4 SWOT Analysis
22 Other Reports in this Series